International Clinical Trial: A Study on the Safety, Tolerability, Bioavailability and Mechanism of Action of subcutaneous NAV-242 in adults with Hidradenitis Suppurativa

Geneva, Feb. 13 -- International Clinical Trials Registry received information related to the study (ACTRN12626000154303) titled 'A Study on the Safety, Tolerability, Bioavailability and Mechanism of Action of subcutaneous NAV-242 in adults with Hidradenitis Suppurativa' on Feb. 6.

Study Type: Interventional

Study Design: Purpose: Treatment Allocation: Non-randomised trial Masking: Open (masking not used) Type of endpoint: Safety/efficacy

Primary Sponsor: Navigator Medicines

Condition: Hidradenitis Suppurativa Hidradenitis Suppurativa Inflammatory and Immune System - Autoimmune diseases

Intervention: This is a Phase 1 open label study to evaluate the safety, tolerability, Pharmacokinetics (PK), Pharmacodynamic(PD), and immunogenic...